시장보고서

상품코드

1800960

다발성 경화증 치료제 시장 보고서 : 약물, 약물 유형, 투여 경로, 유통 채널, 지역별(2025-2033년)

Multiple Sclerosis Therapies Market Report by Drug, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

발행일: 2025년 08월 | 리서치사:

IMARC | 페이지 정보: 영문 120 Pages | 배송안내 : 2-3일 (영업일 기준)

샘플 요청 목록에 추가

※ 본 상품은 영문 자료로 한글과 영문 목차에 불일치하는 내용이 있을 경우 영문을 우선합니다. 정확한 검토를 위해 영문 목차를 참고해주시기 바랍니다.

세계 다발성 경화증 치료제 시장 규모는 2024년 279억 달러에 달했습니다. 향후 IMARC Group은 이 시장이 2033년까지 388억 달러에 달하고, 2025-2033년 연평균 성장률(CAGR)은 3.52%를 보일 것으로 예측했습니다.

다발성 경화증(MS)은 척수 및 뇌 신경세포의 탈수초, 축삭 절단, 신경변성을 유발할 수 있는 면역매개성 만성 염증성 질환을 말합니다. 일반적으로 사용되는 치료법으로는 주사제, 경구약, 정맥주사, 근육이완제, 항우울제, 물리치료 등이 있습니다. 주사제에는 인터페론 베타, 글라티라머 아세테이트 등이 있으며, 피하 또는 근육 내로 투여됩니다. 내복약으로는 디메틸 푸마레이트, 테리플루노미드, 클라드리빈 등이 있으며, 정맥주사로는 오크레리주맙, 나탈리주맙, 알렘투주맙 등이 있으며, 정맥주사로는 오크레리주맙, 나탈리주맙, 알렘투주맙 등이 있습니다. 이러한 약물은 재발의 빈도를 최소화하고 환자의 심박수와 혈압을 조절하여 증상 관리를 돕습니다.

재발 완화형 다발성 경화증(RRMS), 원발성 진행성 다발성 경화증(PPMS), 이차성 진행성 다발성 경화증(SPMS), 진행성 재발성 다발성 경화증(PRMS)의 전 세계 유병률 증가는 시장 성장을 가속하는 중요한 요인 중 하나입니다. 또한, 이러한 질병에 취약한 노년층 인구가 증가하고 있는 것도 시장 성장을 가속하고 있습니다. 의료진은 자가면역 발작을 조절하고 다발성경화증 환자의 재발을 예방하기 위해 면역억제제를 광범위하게 사용하고 있습니다. 또한, 효과적인 다발성 경화증 치료를 위한 혁신적인 단일클론체, 면역조절제, 면역억제제, 인터페론의 개발 등 다양한 기술적 진보가 또 다른 주요 성장 촉진요인으로 작용하고 있습니다. 이와는 별개로, 선진국과 신흥국을 막론하고 각국 정부는 대중에게 치료법에 대한 인식을 높이기 위한 캠페인을 전개하고 있으며, 이는 결국 시장에 밝은 전망을 가져다주고 있습니다. 기타 요인으로는 광범위한 연구개발(R&D) 활동, 헬스케어 인프라 개선 등이 시장을 더욱 견인할 것으로 예측됩니다.

본 보고서에서 다룬 주요 질문

세계 다발성 경화증 치료제 시장은 지금까지 어떻게 성장해왔고, 앞으로 어떻게 변화할 것인가?
코로나19가 세계 다발성 경화증 치료제 시장에 미치는 영향은?
주요 지역 시장은?
약품별 시장 분석은?
약제 유형별 시장 현황은?
투여경로별 시장 현황은?
판매 채널별 시장 현황은?
산업 가치사슬의 다양한 단계는?
업계의 주요 촉진요인과 과제는?
세계 다발성 경화증 치료제 시장 구조와 주요 기업은?
업계 내 경쟁은 어느 정도인가?

Multiple sclerosis (MS) refers to a chronic and inflammatory immune-mediated condition that can cause demyelination, axonal transection and neurodegeneration of the nerve cells in the spinal cord and brain. Some of the commonly used therapies include the administration of injectable, oral and infused medicines, muscle relaxants, antidepressants and physical therapy. The injectable medication, such as Interferon-beta and Glatiramer acetate, are administered under the skin or into the muscle; oral medications include Dimethyl fumarate, Teriflunomide and Cladribine; and infusion treatments include Ocrelizumab, Natalizumab and Alemtuzumab, which are administered intravenously. These medicines aid in managing the symptoms to minimize the frequency of the relapses and control the heart rate and blood pressure of the patient.

The increasing prevalence of relapsing-remitting multiple sclerosis (RRMS), primary-progressive MS (PPMS), secondary-progressive MS (SPMS) and progressive-relapsing MS (PRMS) across the globe, is one of the key factors driving the growth of the market. Furthermore, the rising geriatric population, which is more susceptible to such ailments, is providing a thrust to the market growth. Healthcare providers are widely using immunosuppressants that control autoimmune attacks and prevent relapses among patients suffering from MS. Additionally, various technological advancements, such as the development of innovative monoclonal bodies, immunomodulators, immunosuppressants and interferons for the effective treatment of MS, are acting as other major growth-inducing factors. Apart from this, governments of both the developed and emerging countries are launching campaigns to increase awareness regarding the available treatment alternatives among the masses, which, in turn, is creating a positive outlook for the market. Other factors, including extensive research and development (R&D) activities, along with the improvements in the healthcare infrastructure, are anticipated to drive the market further.

Key Market Segmentation:

Breakup by Drug:

Immunomodulators
- Copaxone
- Avonex/Plegridy
- Gilneya
- Tysabri
- Betaseron/Extavia
- Tecifidera
- Rebif
- Ampyra
Immunosuppressants
- Aubagio
- Lemtrada
- Ocrelizumab
- Zinbryta

Breakup by Drug Type:

Biologic Drugs
Small Molecule Drugs

Breakup by Route of Administration:

Oral
Injectable
Intravenous

Breakup by Distribution Channel:

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

Breakup by Region:

North America
- United States
- Canada
Asia Pacific
- China
- Japan
- India
- South Korea
- Australia
- Indonesia
- Others
Europe
- Germany
- France
- United Kingdom
- Italy
- Spain
- Russia
- Others
Latin America
- Brazil
- Mexico
- Others
Middle East and Africa

Competitive Landscape:

The report has also analysed the competitive landscape of the market with some of the key players being Abbvie Inc., Bayer Aktiengesellschaft, Biogen Inc., Bristol-Myers Squibb Company, F. Hoffmann-La Roche AG (Roche Holding AG), GlaxoSmithKline Plc, Merck & Co. Inc., Novartis AG, Sanofi S.A. and Teva Pharmaceutical Industries Ltd.

Key Questions Answered in This Report:

How has the global multiple sclerosis therapies market performed so far and how will it perform in the coming years?
What has been the impact of COVID-19 on the global multiple sclerosis therapies market?
What are the key regional markets?
What is the breakup of the market based on the drug?
What is the breakup of the market based on the drug type?
What is the breakup of the market based on the route of administration?
What is the breakup of the market based on the distribution channel?
What are the various stages in the value chain of the industry?
What are the key driving factors and challenges in the industry?
What is the structure of the global multiple sclerosis therapies market and who are the key players?
What is the degree of competition in the industry?

1 Preface

2 Scope and Methodology

2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
- 2.3.1 Primary Sources
- 2.3.2 Secondary Sources
2.4 Market Estimation
- 2.4.1 Bottom-Up Approach
- 2.4.2 Top-Down Approach
2.5 Forecasting Methodology

3 Executive Summary

4 Introduction

4.1 Overview
4.2 Key Industry Trends

5 Global Multiple Sclerosis Therapies Market

5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast

6 Market Breakup by Drug

6.1 Immunomodulators
- 6.1.1 Market Trends
- 6.1.2 Major Types
  - 6.1.2.1 Copaxone
  - 6.1.2.2 Avonex/Plegridy
  - 6.1.2.3 Gilneya
  - 6.1.2.4 Tysabri
  - 6.1.2.5 Betaseron/Extavia
  - 6.1.2.6 Tecifidera
  - 6.1.2.7 Rebif
  - 6.1.2.8 Ampyra
- 6.1.3 Market Forecast
6.2 Immunosuppressants
- 6.2.1 Market Trends
- 6.2.2 Major Types
  - 6.2.2.1 Aubagio
  - 6.2.2.2 Lemtrada
  - 6.2.2.3 Ocrelizumab
  - 6.2.2.4 Zinbryta
- 6.2.3 Market Forecast

7 Market Breakup by Drug Type

7.1 Biologic Drugs
- 7.1.1 Market Trends
- 7.1.2 Market Forecast
7.2 Small Molecule Drugs
- 7.2.1 Market Trends
- 7.2.2 Market Forecast

8 Market Breakup by Route of Administration

8.1 Oral
- 8.1.1 Market Trends
- 8.1.2 Market Forecast
8.2 Injectable
- 8.2.1 Market Trends
- 8.2.2 Market Forecast
8.3 Intravenous
- 8.3.1 Market Trends
- 8.3.2 Market Forecast

9 Market Breakup by Distribution Channel

9.1 Hospital Pharmacies
- 9.1.1 Market Trends
- 9.1.2 Market Forecast
9.2 Retail Pharmacies
- 9.2.1 Market Trends
- 9.2.2 Market Forecast
9.3 Online Pharmacies
- 9.3.1 Market Trends
- 9.3.2 Market Forecast

10 Market Breakup by Region

10.1 North America
- 10.1.1 United States
  - 10.1.1.1 Market Trends
  - 10.1.1.2 Market Forecast
- 10.1.2 Canada
  - 10.1.2.1 Market Trends
  - 10.1.2.2 Market Forecast
10.2 Asia Pacific
- 10.2.1 China
  - 10.2.1.1 Market Trends
  - 10.2.1.2 Market Forecast
- 10.2.2 Japan
  - 10.2.2.1 Market Trends
  - 10.2.2.2 Market Forecast
- 10.2.3 India
  - 10.2.3.1 Market Trends
  - 10.2.3.2 Market Forecast
- 10.2.4 South Korea
  - 10.2.4.1 Market Trends
  - 10.2.4.2 Market Forecast
- 10.2.5 Australia
  - 10.2.5.1 Market Trends
  - 10.2.5.2 Market Forecast
- 10.2.6 Indonesia
  - 10.2.6.1 Market Trends
  - 10.2.6.2 Market Forecast
- 10.2.7 Others
  - 10.2.7.1 Market Trends
  - 10.2.7.2 Market Forecast
10.3 Europe
- 10.3.1 Germany
  - 10.3.1.1 Market Trends
  - 10.3.1.2 Market Forecast
- 10.3.2 France
  - 10.3.2.1 Market Trends
  - 10.3.2.2 Market Forecast
- 10.3.3 United Kingdom
  - 10.3.3.1 Market Trends
  - 10.3.3.2 Market Forecast
- 10.3.4 Italy
  - 10.3.4.1 Market Trends
  - 10.3.4.2 Market Forecast
- 10.3.5 Spain
  - 10.3.5.1 Market Trends
  - 10.3.5.2 Market Forecast
- 10.3.6 Russia
  - 10.3.6.1 Market Trends
  - 10.3.6.2 Market Forecast
- 10.3.7 Others
  - 10.3.7.1 Market Trends
  - 10.3.7.2 Market Forecast
10.4 Latin America
- 10.4.1 Brazil
  - 10.4.1.1 Market Trends
  - 10.4.1.2 Market Forecast
- 10.4.2 Mexico
  - 10.4.2.1 Market Trends
  - 10.4.2.2 Market Forecast
- 10.4.3 Others
  - 10.4.3.1 Market Trends
  - 10.4.3.2 Market Forecast
10.5 Middle East and Africa
- 10.5.1 Market Trends
- 10.5.2 Market Breakup by Country
- 10.5.3 Market Forecast

11 SWOT Analysis

11.1 Overview
11.2 Strengths
11.3 Weaknesses
11.4 Opportunities
11.5 Threats

12 Value Chain Analysis

13 Porters Five Forces Analysis

13.1 Overview
13.2 Bargaining Power of Buyers
13.3 Bargaining Power of Suppliers
13.4 Degree of Competition
13.5 Threat of New Entrants
13.6 Threat of Substitutes

14 Price Analysis

15 Competitive Landscape

15.1 Market Structure
15.2 Key Players
15.3 Profiles of Key Players
- 15.3.1 Abbvie Inc.
  - 15.3.1.1 Company Overview
  - 15.3.1.2 Product Portfolio
  - 15.3.1.3 Financials
  - 15.3.1.4 SWOT Analysis
- 15.3.2 Bayer Aktiengesellschaft
  - 15.3.2.1 Company Overview
  - 15.3.2.2 Product Portfolio
  - 15.3.2.3 Financials
  - 15.3.2.4 SWOT Analysis
- 15.3.3 Biogen Inc.
  - 15.3.3.1 Company Overview
  - 15.3.3.2 Product Portfolio
  - 15.3.3.3 Financials
  - 15.3.3.4 SWOT Analysis
- 15.3.4 Bristol-Myers Squibb Company
  - 15.3.4.1 Company Overview
  - 15.3.4.2 Product Portfolio
  - 15.3.4.3 Financials
  - 15.3.4.4 SWOT Analysis
- 15.3.5 F. Hoffmann-La Roche AG (Roche Holding AG)
  - 15.3.5.1 Company Overview
  - 15.3.5.2 Product Portfolio
  - 15.3.5.3 SWOT Analysis
- 15.3.6 GlaxoSmithKline Plc
  - 15.3.6.1 Company Overview
  - 15.3.6.2 Product Portfolio
  - 15.3.6.3 Financials
  - 15.3.6.4 SWOT Analysis
- 15.3.7 Merck & Co. Inc.
  - 15.3.7.1 Company Overview
  - 15.3.7.2 Product Portfolio
  - 15.3.7.3 Financials
  - 15.3.7.4 SWOT Analysis
- 15.3.8 Novartis AG
  - 15.3.8.1 Company Overview
  - 15.3.8.2 Product Portfolio
  - 15.3.8.3 Financials
  - 15.3.8.4 SWOT Analysis
- 15.3.9 Sanofi S.A.
  - 15.3.9.1 Company Overview
  - 15.3.9.2 Product Portfolio
  - 15.3.9.3 Financials
  - 15.3.9.4 SWOT Analysis
- 15.3.10 Teva Pharmaceutical Industries Ltd.
  - 15.3.10.1 Company Overview
  - 15.3.10.2 Product Portfolio
  - 15.3.10.3 Financials
  - 15.3.10.4 SWOT Analysis

다발성 경화증 치료제 시장 보고서 : 약물, 약물 유형, 투여 경로, 유통 채널, 지역별(2025-2033년)

Multiple Sclerosis Therapies Market Report by Drug, Drug Type, Route of Administration, Distribution Channel, and Region 2025-2033

본 보고서에서 다룬 주요 질문

목차

제1장 서문

제2장 조사 범위와 조사 방법

제3장 주요 요약

제4장 서론

제5장 세계의 다발성 경화증 치료제 시장

제6장 시장 분석 : 약물별

제7장 시장 분석 : 약제 유형별

제8장 시장 분석 : 투여 경로별

제9장 시장 분석 : 유통 채널별

제10장 시장 분석 : 지역별

제11장 SWOT 분석

제12장 밸류체인 분석

제13장 Porter의 Five Forces 분석

제14장 가격 분석

제15장 경쟁 구도